ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

romiplostim

Also written as “Romiplostim”, “AMG 531” and “GNR-069”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Aplastic · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Purpura, Thrombocytopenic, led by 5 companies.

Drug pageRomiplostim: every studyMany companies study it; this page follows only the 38 they lead. All 90 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 21, 200938 company-led studies, 4 open or runningNext primary completion: Mar 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only252 open or runningphase 4since May 21, 2009Jan 27, 2005Sep 14, 2029phase 3 · NCT07700238
Kyowa Kirinits history only80 open or runningphase 3since Feb 22, 2007Mar 20, 2006none ahead
AO GENERIUM20 open or runningphase 3since Jan 21, 2022Jan 21, 2022none ahead
Geropharmits history only21 open or runningphase 3since Jul 4, 2024Dec 7, 2022Mar 31, 2028phase 3 · NCT06497036
Qilu Pharmaceuticalits history only11 open or runningphase 3since Dec 23, 2025Dec 23, 2025Oct 2029phase 3 · NCT07345000

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AO GENERIUM only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 21, 2022First study: phase 3 study in Purpura, Thrombocytopenic, IdiopathicFirst studyNCT05220878 · 160 enrolled · Russian Federation
  2. Aug 3, 2022Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT05492409 · 160 enrolled · Russian Federation

TargetBeta

MPL →read by rule
“Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
eltrombopagruleGlaxoSmithKlinephase 449
avatrombopagruleEisaiphase 425
hetrombopag olamineruleJiangsu HengRui Medicinephase 315

Studies

All 2 AO GENERIUM leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05492409Purpura, Thrombocytopenic, Idiopathic · Russian Federation3CompletedApr 3, 2024160
NCT05220878Purpura, Thrombocytopenic, Idiopathic · Russian Federation3CompletedAug 22, 2023160

How it is read

Names in the registry

  • “Romiplostim”, 22 entries
  • “AMG 531”, 6 entries
  • “GNR-069”, 2 entries
  • “Romiplostim N01”, 1 entry
  • “GP404141”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.